Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Sep 12;23(1):659.
doi: 10.1186/s12903-023-03316-0.

Systematic evaluation of TP53 codon 72 polymorphism associated with onset and progression of oral potentially malignant disorders

Huangkai Li #  1 , Yu Liu #  2   3 , Shanxin Zhou  3 , Qin Zhou  4   5 , Xi Yang  6   7   8
Affiliations
Meta-Analysis

Systematic evaluation of TP53 codon 72 polymorphism associated with onset and progression of oral potentially malignant disorders

Huangkai Li et al. BMC Oral Health. .

Abstract

Background: Recently, a systematic review and meta-analysis demonstrated that overexpression of p53 immunoprotein was significantly associated with progression risk of oral potentially malignant disorders (OPMD). However, the results of investigations on TP53 genetic typing in OPMD were inconsistent and inconclusive.

Methods: A systematic evaluation was conducted to identify all eligible case-control studies on the association of TP53 codon 72 polymorphism with both onset and progression of OPMD.

Results: A total of 768 OPMD patients and 1173 healthy individuals were identified from 12 eligible case-control studies on TP53 codon 72 polymorphism OPMD onset. In overall and subgroup analyses, no significantly risk of OPMD onset was observed in the cases for genetic models including allele C vs. G, homozygote CC vs. GG, heterozygote GC vs. GG, dominant GC + CC vs. GG, and recessive CC vs. GG + GC (all P-value of association test > 0.05). Further, a total of 465 OPMD patients and 775 oral squamous cell carcinoma (OSCC) ones were identified from 8 eligible case-control studies on this polymorphism in OPMD progression to OSCC. The analyses revealed that there was also no significantly risk of OPMD progression in the cases for the genetic models (all P-value of association test > 0.05).

Conclusion: Our data of a pooled-analysis indicates that TP53 codon 72 polymorphism may not act as genetic factor for the risk of OPMD onset and progression. Combined with the conclusion by a systematic review and meta-analysis, we put forward a new opinion that TP53 genetic typing cloud not influence p53 protein expression in OPMD.

Keywords: Meta-analysis; Oral cancer; Oral potentially malignant disorders; Single-nucleotide polymorphisms; TP53.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Detailed genotype distributions and forest plots of TP53 codon 72 polymorphism with OPMD onset compared to healthy control (HC) in five genetic models. A allele C vs. G, B heterozygote GC vs. GG, C homozygote CC vs. GG, D dominant GC + CC vs. GG, E recessive CC vs. GG + GC
Fig. 2
Fig. 2
Detailed genotype distributions and forest plots of TP53 codon 72 polymorphism with OPMD progression to OSCC in five genetic models. A allele C vs. G, B heterozygote GC vs. GG, C homozygote CC vs. GG, D dominant GC + CC vs. GG, E recessive CC vs. GG + GC
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Warnakulasuriya S, Kujan O, Aguirre-Urizar JM, et al. Oral potentially malignant disorders: a consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral Dis. 2021;27:1862–1880. doi: 10.1111/odi.13704. - DOI - PubMed
    1. Farah CS. Molecular, genomic and mutational landscape of oral leukoplakia. Oral Dis. 2021;27(4):803–812. doi: 10.1111/odi.13608. - DOI - PubMed
    1. Singh RD, Patel KA, Patel JB, Patel PS. Alterations in p53 Influence hTERT, VEGF and MMPs expression in oral cancer patients. Asian Pac J Cancer Prev. 2022;23(9):3141–3149. doi: 10.31557/APJCP.2022.23.9.3141. - DOI - PMC - PubMed
    1. Shridhar K, Aggarwal A, Walia GK, Gulati S, Geetha AV, Prabhakaran D, et al. Single nucleotide polymorphisms as markers of genetic susceptibility for oral potentially malignant disorders risk: Review of evidence to date. Oral Oncol. 2016;61:146–151. doi: 10.1016/j.oraloncology.2016.08.005. - DOI - PMC - PubMed
    1. Yasasve M, Manjusha M, Saravanan M. Polymorphism in pro-inflammatory cytokines and their genetic susceptibility towards oral precancerous lesions and oral cancer. Oral Oncol. 2022;133:106027. doi: 10.1016/j.oraloncology.2022.106027. - DOI - PubMed

Publication types

MeSH terms